The Future of the Generics Landscape: Key Branded Drugs Losing Exclusivity in 2021 and Beyond
Information
Despite the many challenges the biopharma industry, and the world, has faced since the start of the pandemic, one thing remains certain – patients need access to affordable, lifesaving therapies. Now more than ever, generic drugs provide cost effective treatments to patients who may otherwise not have affordable treatment options.
Over the next 5 years, 6 single ingredient drugs are set to lose exclusivity in the most competitive markets – U.S., EU Top 5, and Japan.
Join a Clarivate expert to uncover the unique qualities of these drugs that give them the potential to transform the generics landscape. You'll learn:
- What does the loss of exclusivity pipeline in the U.S., EU Top 5, and Japan look like over the course of 2021?
- What are the top three brands in each region according to 2020 global sales by molecule?
- Which two drugs losing exclusivity from 2021-2026 will be particularly competitive due to factors outside of sales numbers?
- Which therapeutic area that has a large amount of branded drugs expected to lose exclusivity in the next 5 years?
